Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sensicold
- Development stage
- Phase 3
- Lead developer
- Docventures
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sensicold is a fixed-dose combination oral syrup developed and marketed by Docventures Pharmaceuticals for the symptomatic relief of the common cold, influenza, and allergic rhinitis. The formulation contains three active small molecule ingredients: paracetamol (acetaminophen), phenylephrine hydrochloride, and chlorpheniramine maleate. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine hydrochloride acts as a sympathomimetic nasal decongestant by stimulating alpha-1 adrenergic receptors to induce vasoconstriction in the nasal mucosa. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors to alleviate allergic symptoms such as sneezing, rhinorrhea, and watery eyes. The product is primarily marketed in India for both pediatric and adult use.
- Brand names
- Sensicold
- Other names
- Paracetamol + Phenylephrine + Chlorpheniramine syrup
02
Targets
ADRA1A (α1A)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on Sensicold.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sensicold.